Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma
Status:
Completed
Trial end date:
2011-04-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and the safety profile and toxicity of
a combination of Velcade™ (bortezomib) with a standard chemotherapy regimen (ACVBP
[doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone]) in the treatment of
previously untreated patients with peripheral T-cell lymphoma (PTCL).